-
1
-
-
0032546844
-
The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
-
R. Wyatt, and J.G. Sodroski The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens Science 280 1998 1884 1888
-
(1998)
Science
, vol.280
, pp. 1884-1888
-
-
Wyatt, R.1
Sodroski, J.G.2
-
2
-
-
0023908974
-
Mode of insertion into a lipid membrane of the N-terminal HIV gp41 peptide segment
-
R. Brasseur, B. Cornet, A. Burny, M. Vandenbranden, and J.M. Ruysschaert Mode of insertion into a lipid membrane of the N-terminal HIV gp41 peptide segment AIDS Res. Hum. Retroviruses 4 1988 83 90
-
(1988)
AIDS Res. Hum. Retroviruses
, vol.4
, pp. 83-90
-
-
Brasseur, R.1
Cornet, B.2
Burny, A.3
Vandenbranden, M.4
Ruysschaert, J.M.5
-
3
-
-
0037301373
-
Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites
-
Y. He, R. Vassell, M. Zaitseva, N. Nguyen, Z. Yang, Y. Weng, and C.D. Weiss Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites J. Virol. 77 2003 1666 1671
-
(2003)
J. Virol.
, vol.77
, pp. 1666-1671
-
-
He, Y.1
Vassell, R.2
Zaitseva, M.3
Nguyen, N.4
Yang, Z.5
Weng, Y.6
Weiss, C.D.7
-
4
-
-
0031010455
-
Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell fusion - Structure-function study
-
Y. Kliger, A. Aharoni, D. Rapaport, P. Jones, R. Blumenthal, and Y. Shai Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell fusion - structure-function study J. Biol. Chem. 272 1997 13496 13505
-
(1997)
J. Biol. Chem.
, vol.272
, pp. 13496-13505
-
-
Kliger, Y.1
Aharoni, A.2
Rapaport, D.3
Jones, P.4
Blumenthal, R.5
Shai, Y.6
-
5
-
-
0030780614
-
Atomic structure of a thermostable subdomain of HIV-1 gp41
-
K. Tan, J. Liu, J. Wang, S. Shen, and M. Liu Atomic structure of a thermostable subdomain of HIV-1 gp41 Proc. Natl. Acad. Sci. U. S. A. 94 1997 12303 12308
-
(1997)
Proc. Natl. Acad. Sci. U. S. A.
, vol.94
, pp. 12303-12308
-
-
Tan, K.1
Liu, J.2
Wang, J.3
Shen, S.4
Liu, M.5
-
6
-
-
0030970693
-
Core structure of gp41 from the HIV envelope glycoprotein
-
D.C. Chan, D. Fass, J.M. Berger, and P.S. Kim Core structure of gp41 from the HIV envelope glycoprotein Cell 89 1997 263 273
-
(1997)
Cell
, vol.89
, pp. 263-273
-
-
Chan, D.C.1
Fass, D.2
Berger, J.M.3
Kim, P.S.4
-
7
-
-
0030962291
-
Atomic structure of the ectodomain from HIV-1 gp41
-
W. Weissenhorn, A. Dessen, S.C. Harrison, J.J. Skehel, and D.C. Wiley Atomic structure of the ectodomain from HIV-1 gp41 Nature 387 1997 426 428
-
(1997)
Nature
, vol.387
, pp. 426-428
-
-
Weissenhorn, W.1
Dessen, A.2
Harrison, S.C.3
Skehel, J.J.4
Wiley, D.C.5
-
8
-
-
0031959601
-
Capture of an early fusion-active comformation of HIV-1 gp41
-
R. Furuta, C.T. Wild, Y. Weng, and C.D. Weiss Capture of an early fusion-active comformation of HIV-1 gp41 Nat. Struct. Biol. 5 1998 276 279
-
(1998)
Nat. Struct. Biol.
, vol.5
, pp. 276-279
-
-
Furuta, R.1
Wild, C.T.2
Weng, Y.3
Weiss, C.D.4
-
9
-
-
0034645796
-
Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation
-
Y. Kliger, and Y. Shai Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation J. Mol. Biol. 295 2000 163 168
-
(2000)
J. Mol. Biol.
, vol.295
, pp. 163-168
-
-
Kliger, Y.1
Shai, Y.2
-
10
-
-
0027203897
-
Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41
-
S. Jiang, K. Lin, N. Strick, and A.R. Neurath Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41 Biochem. Biophys. Res. Commun. 195 1993 533 538
-
(1993)
Biochem. Biophys. Res. Commun.
, vol.195
, pp. 533-538
-
-
Jiang, S.1
Lin, K.2
Strick, N.3
Neurath, A.R.4
-
12
-
-
0028575843
-
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex
-
C. Wild, J.W. Dubay, T. Greenwell, T. Baird Jr., T.G. Oas, C. McDanal, E. Hunter, and T. Matthews Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex Proc. Natl. Acad. Sci. U. S. A. 91 1994 12676 12680
-
(1994)
Proc. Natl. Acad. Sci. U. S. A.
, vol.91
, pp. 12676-12680
-
-
Wild, C.1
Dubay, J.W.2
Greenwell, T.3
Baird, Jr.T.4
Oas, T.G.5
McDanal, C.6
Hunter, E.7
Matthews, T.8
-
13
-
-
0027692502
-
A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion
-
C. Wild, T. Greenwell, and T. Matthews A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion AIDS Res. Hum. Retroviruses 9 1993 1051 1053
-
(1993)
AIDS Res. Hum. Retroviruses
, vol.9
, pp. 1051-1053
-
-
Wild, C.1
Greenwell, T.2
Matthews, T.3
-
14
-
-
0031441562
-
A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein
-
M. Lu, and P.S. Kim A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein J. Biomol. Struct. Dyn. 15 1997 465 471
-
(1997)
J. Biomol. Struct. Dyn.
, vol.15
, pp. 465-471
-
-
Lu, M.1
Kim, P.S.2
-
15
-
-
0026465468
-
A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition
-
C. Wild, T. Oas, C. McDanal, D. Bolognesi, and T. Matthews A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition Proc. Natl. Acad. Sci. U. S. A. 89 1992 10537 10541
-
(1992)
Proc. Natl. Acad. Sci. U. S. A.
, vol.89
, pp. 10537-10541
-
-
Wild, C.1
Oas, T.2
McDanal, C.3
Bolognesi, D.4
Matthews, T.5
-
16
-
-
0038671938
-
The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation
-
J.J. Dwyer, A. Hasan, K.L. Wilson, J.M. White, T.J. Matthews, and M.K. Delmedico The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation Biochemistry 42 2003 4945 4953
-
(2003)
Biochemistry
, vol.42
, pp. 4945-4953
-
-
Dwyer, J.J.1
Hasan, A.2
Wilson, K.L.3
White, J.M.4
Matthews, T.J.5
Delmedico, M.K.6
-
17
-
-
67650745033
-
The role of amphiphilicity and negative charge in glycoprotein 41 interactions in the hydrophobic pocket
-
M. Gochin The role of amphiphilicity and negative charge in glycoprotein 41 interactions in the hydrophobic pocket J. Med. Chem. 2009 4338 4344
-
(2009)
J. Med. Chem.
, pp. 4338-4344
-
-
Gochin, M.1
-
18
-
-
0032433685
-
Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target
-
D.C. Chan, C.T. Chutkowski, and P.S. Kim Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target Proc. Natl. Acad. Sci. U. S. A. 95 1998 15613 15617
-
(1998)
Proc. Natl. Acad. Sci. U. S. A.
, vol.95
, pp. 15613-15617
-
-
Chan, D.C.1
Chutkowski, C.T.2
Kim, P.S.3
-
19
-
-
0032850583
-
Inhibition of HIV-1 infectivity by the gp41 core: Role of a conserved hydrophobic cavity in membrane fusion
-
H. Ji, W. Shu, T. Burling, S. Jiang, and M. Lu Inhibition of HIV-1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion J. Virol. 73 1999 8578 8586
-
(1999)
J. Virol.
, vol.73
, pp. 8578-8586
-
-
Ji, H.1
Shu, W.2
Burling, T.3
Jiang, S.4
Lu, M.5
-
20
-
-
57649155175
-
Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors
-
Z. Qi, W. Shi, N. Xue, C. Pan, W. Jing, K. Liu, and S. Jiang Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors J. Biol. Chem. 283 2008 30376 30384
-
(2008)
J. Biol. Chem.
, vol.283
, pp. 30376-30384
-
-
Qi, Z.1
Shi, W.2
Xue, N.3
Pan, C.4
Jing, W.5
Liu, K.6
Jiang, S.7
-
21
-
-
34248155890
-
HIV gp41 C-terminal heptad repeat contains multifunctional domains: Relation to mechanisms of action of anti-HIV peptides
-
S. Liu, W. Jing, B. Cheung, H. Lu, J. Sun, X. Yan, J. Niu, J. Farmar, S. Wu, and S. Jiang HIV gp41 C-terminal heptad repeat contains multifunctional domains: relation to mechanisms of action of anti-HIV peptides J. Biol. Chem. 282 2007 9612 9620
-
(2007)
J. Biol. Chem.
, vol.282
, pp. 9612-9620
-
-
Liu, S.1
Jing, W.2
Cheung, B.3
Lu, H.4
Sun, J.5
Yan, X.6
Niu, J.7
Farmar, J.8
Wu, S.9
Jiang, S.10
-
22
-
-
15744393651
-
Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120
-
S. Liu, H. Lu, Y. Xu, S. Wu, and S. Jiang Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120 J. Biol. Chem. 280 2005 11259 11273
-
(2005)
J. Biol. Chem.
, vol.280
, pp. 11259-11273
-
-
Liu, S.1
Lu, H.2
Xu, Y.3
Wu, S.4
Jiang, S.5
-
23
-
-
3042606321
-
Peptide inhibitors of virus-cell fusion: Enfuvirtide as a case study in clinical discovery and development
-
D.A. Cooper, and J.M. Lange Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development Lancet Infect. Dis. 4 2004 426 436
-
(2004)
Lancet Infect. Dis.
, vol.4
, pp. 426-436
-
-
Cooper, D.A.1
Lange, J.M.2
-
24
-
-
0038187684
-
Novel therapies based on mechanisms of HIV-1 cell entry, N.Engl
-
J.M. Kilby, and J.J. Eron Novel therapies based on mechanisms of HIV-1 cell entry, N.Engl J. Med. 348 2003 2228 2238
-
(2003)
J. Med.
, vol.348
, pp. 2228-2238
-
-
Kilby, J.M.1
Eron, J.J.2
-
25
-
-
0036090585
-
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
-
X. Wei, J.M. Decker, H. Liu, Z. Zhang, R.B. Arani, J.M. Kilby, M.S. Saag, X. Wu, G.M. Shaw, and J.C. Kappes Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy Antimicrob. Agents Chemother. 46 2002 1896 1905
-
(2002)
Antimicrob. Agents Chemother.
, vol.46
, pp. 1896-1905
-
-
Wei, X.1
Decker, J.M.2
Liu, H.3
Zhang, Z.4
Arani, R.B.5
Kilby, J.M.6
Saag, M.S.7
Wu, X.8
Shaw, G.M.9
Kappes, J.C.10
-
26
-
-
25144489604
-
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro
-
M. Mink, S.M. Mosier, S. Janumpalli, D. Davison, L. Jin, T. Melby, P. Sista, J. Erickson, D. Lambert, S.A. Stanfield-Oakley, M. Salgo, N. Cammack, T. Matthews, and M.L. Greenberg Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro J. Virol. 79 2005 12447 12454
-
(2005)
J. Virol.
, vol.79
, pp. 12447-12454
-
-
Mink, M.1
Mosier, S.M.2
Janumpalli, S.3
Davison, D.4
Jin, L.5
Melby, T.6
Sista, P.7
Erickson, J.8
Lambert, D.9
Stanfield-Oakley, S.A.10
Salgo, M.11
Cammack, N.12
Matthews, T.13
Greenberg, M.L.14
-
27
-
-
45749135859
-
Selection of T1249-resistant human immunodeficiency virus type 1 variants
-
D. Eggink, C.E. Baldwin, Y. Deng, J.P. Langedijk, M. Lu, R.W. Sanders, and B. Berkhout Selection of T1249-resistant human immunodeficiency virus type 1 variants J. Virol. 82 2008 6678 6688
-
(2008)
J. Virol.
, vol.82
, pp. 6678-6688
-
-
Eggink, D.1
Baldwin, C.E.2
Deng, Y.3
Langedijk, J.P.4
Lu, M.5
Sanders, R.W.6
Berkhout, B.7
-
28
-
-
0031883832
-
Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides
-
L.T. Rimsky, D.C. Shugars, and T.J. Matthews Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides J. Virol. 72 1998 986 993
-
(1998)
J. Virol.
, vol.72
, pp. 986-993
-
-
Rimsky, L.T.1
Shugars, D.C.2
Matthews, T.J.3
-
29
-
-
63149093637
-
HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide
-
N. Ray, L.A. Blackburn, and R.W. Doms HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide J. Virol. 83 2009 2989 2995
-
(2009)
J. Virol.
, vol.83
, pp. 2989-2995
-
-
Ray, N.1
Blackburn, L.A.2
Doms, R.W.3
-
30
-
-
33947417638
-
Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors
-
N. Ray, J.E. Harrison, L.A. Blackburn, J.N. Martin, S.G. Deeks, and R.W. Doms Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors J. Virol. 81 2007 3240 3250
-
(2007)
J. Virol.
, vol.81
, pp. 3240-3250
-
-
Ray, N.1
Harrison, J.E.2
Blackburn, L.A.3
Martin, J.N.4
Deeks, S.G.5
Doms, R.W.6
-
32
-
-
0037936885
-
C-terminal octylation rescues an inactive T20 mutant: Implications for the mechanism of HIV/SIV-induced membrane fusion
-
S.G. Peisajovich, S.A. Gallo, R. Blumenthal, and Y. Shai C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIV-induced membrane fusion J. Biol. Chem. 278 2003 21012 21017
-
(2003)
J. Biol. Chem.
, vol.278
, pp. 21012-21017
-
-
Peisajovich, S.G.1
Gallo, S.A.2
Blumenthal, R.3
Shai, Y.4
-
33
-
-
0035846960
-
Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage
-
Y. Kliger, S.A. Gallo, S.G. Peisajovich, I. Munoz-Barroso, S. Avkin, R. Blumenthal, and Y. Shai Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage J. Biol. Chem. 276 2001 1391 1397
-
(2001)
J. Biol. Chem.
, vol.276
, pp. 1391-1397
-
-
Kliger, Y.1
Gallo, S.A.2
Peisajovich, S.G.3
Munoz-Barroso, I.4
Avkin, S.5
Blumenthal, R.6
Shai, Y.7
-
34
-
-
0014109212
-
Spectroscopic determination of tryptophan and tyrosine in proteins
-
H. Edelhoch Spectroscopic determination of tryptophan and tyrosine in proteins Biochemistry 6 1967 1948 1954
-
(1967)
Biochemistry
, vol.6
, pp. 1948-1954
-
-
Edelhoch, H.1
-
35
-
-
0034023726
-
Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41
-
Y. Weng, Z. Yang, and C.D. Weiss Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41 J. Virol. 74 2000 5368 5372
-
(2000)
J. Virol.
, vol.74
, pp. 5368-5372
-
-
Weng, Y.1
Yang, Z.2
Weiss, C.D.3
-
36
-
-
16244367157
-
Human immunodeficiency virus (HIV) gp41 escape mutants: Cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120
-
E. Desmezieres, N. Gupta, R. Vassell, Y. He, K. Peden, L. Sirota, Z. Yang, P. Wingfield, and C.D. Weiss Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120 J. Virol. 79 2005 4774 4781
-
(2005)
J. Virol.
, vol.79
, pp. 4774-4781
-
-
Desmezieres, E.1
Gupta, N.2
Vassell, R.3
He, Y.4
Peden, K.5
Sirota, L.6
Yang, Z.7
Wingfield, P.8
Weiss, C.D.9
-
37
-
-
84862927851
-
Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket
-
X. Yu, L. Lu, L. Cai, P. Tong, S. Tan, P. Zou, F. Meng, Y.H. Chen, and S. Jiang Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket J. Virol. 86 2012 589 593
-
(2012)
J. Virol.
, vol.86
, pp. 589-593
-
-
Yu, X.1
Lu, L.2
Cai, L.3
Tong, P.4
Tan, S.5
Zou, P.6
Meng, F.7
Chen, Y.H.8
Jiang, S.9
-
38
-
-
0034701058
-
Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides
-
W. Shu, J. Liu, H. Ji, L. Radigan, S. Jiang, and M. Lu Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides Biochemistry 39 2000 1634 1642
-
(2000)
Biochemistry
, vol.39
, pp. 1634-1642
-
-
Shu, W.1
Liu, J.2
Ji, H.3
Radigan, L.4
Jiang, S.5
Lu, M.6
-
39
-
-
0346729750
-
Determination of the HIV-1 gp41 postfusion conformation modeled by synthetic peptides: Applicable for identification of the HIV-1 fusion inhibitors
-
S. Liu, Q. Zhao, and S. Jiang Determination of the HIV-1 gp41 postfusion conformation modeled by synthetic peptides: applicable for identification of the HIV-1 fusion inhibitors Peptide 24 2003 1303 1313
-
(2003)
Peptide
, vol.24
, pp. 1303-1313
-
-
Liu, S.1
Zhao, Q.2
Jiang, S.3
-
40
-
-
7244253012
-
N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion
-
S. Jiang, H. Lu, S. Liu, Q. Zhao, Y. He, and A.K. Debnath N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion Antimicrob. Agents Chemother. 48 2004 4349 4359
-
(2004)
Antimicrob. Agents Chemother.
, vol.48
, pp. 4349-4359
-
-
Jiang, S.1
Lu, H.2
Liu, S.3
Zhao, Q.4
He, Y.5
Debnath, A.K.6
-
41
-
-
77951216905
-
3-Hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: A potential microbicide for preventing sexual transmission of HIV-1
-
L. Li, L. He, S. Tan, X. Guo, H. Lu, Z. Qi, C. Pan, X. An, S. Jiang, and S. Liu 3-Hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1 Antimicrob. Agents Chemother. 54 2010 1700 1711
-
(2010)
Antimicrob. Agents Chemother.
, vol.54
, pp. 1700-1711
-
-
Li, L.1
He, L.2
Tan, S.3
Guo, X.4
Lu, H.5
Qi, Z.6
Pan, C.7
An, X.8
Jiang, S.9
Liu, S.10
-
42
-
-
67749147470
-
Combinations of the first and next generation HIV fusion inhibitors exhibit highly potent synergistic effect against enfuvirtide-sensitive and resistant HIV-1 strains
-
C. Pan, L. Cai, H. Lu, Z. Qi, and S. Jiang Combinations of the first and next generation HIV fusion inhibitors exhibit highly potent synergistic effect against enfuvirtide-sensitive and resistant HIV-1 strains J. Virol. 83 2009 7862 7872
-
(2009)
J. Virol.
, vol.83
, pp. 7862-7872
-
-
Pan, C.1
Cai, L.2
Lu, H.3
Qi, Z.4
Jiang, S.5
-
43
-
-
33748794547
-
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
-
T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 58 2006 621 681
-
(2006)
Pharmacol. Rev.
, vol.58
, pp. 621-681
-
-
Chou, T.C.1
-
44
-
-
0021118703
-
Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
-
T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
-
(1984)
Adv. Enzyme Regul.
, vol.22
, pp. 27-55
-
-
Chou, T.C.1
Talalay, P.2
-
45
-
-
0031798443
-
Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41
-
Y. Weng, and C.D. Weiss Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41 J. Virol. 72 1998 9676 9682
-
(1998)
J. Virol.
, vol.72
, pp. 9676-9682
-
-
Weng, Y.1
Weiss, C.D.2
-
46
-
-
0032850583
-
Inhibition of HIV-1 infectivity by the gp41 core: Role of a conserved hydrophobic cavity in membrane fusion
-
H. Ji, W. Shu, T. Burling, S. Jiang, and M. Lu Inhibition of HIV-1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion J. Virol. 73 1999 8578 8586
-
(1999)
J. Virol.
, vol.73
, pp. 8578-8586
-
-
Ji, H.1
Shu, W.2
Burling, T.3
Jiang, S.4
Lu, M.5
-
47
-
-
0036066762
-
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults
-
J.M. Kilby, J.P. Lalezari, J.J. Eron, M. Carlson, C. Cohen, R.C. Arduino, J.C. Goodgame, J.E. Gallant, P. Volberding, R.L. Murphy, F. Valentine, M.S. Saag, E.L. Nelson, P.R. Sista, and A. Dusek The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults AIDS Res. Hum. Retroviruses 18 2002 685 693
-
(2002)
AIDS Res. Hum. Retroviruses
, vol.18
, pp. 685-693
-
-
Kilby, J.M.1
Lalezari, J.P.2
Eron, J.J.3
Carlson, M.4
Cohen, C.5
Arduino, R.C.6
Goodgame, J.C.7
Gallant, J.E.8
Volberding, P.9
Murphy, R.L.10
Valentine, F.11
Saag, M.S.12
Nelson, E.L.13
Sista, P.R.14
Dusek, A.15
-
48
-
-
0031729823
-
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
-
J.M. Kilby, S. Hopkins, T.M. Venetta, B. DiMassimo, G.A. Cloud, J.Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M.R. Johnson, M.A. Nowak, G.M. Shaw, and M.S. Saag Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry Nat. Med. 4 1998 1302 1307
-
(1998)
Nat. Med.
, vol.4
, pp. 1302-1307
-
-
Kilby, J.M.1
Hopkins, S.2
Venetta, T.M.3
Dimassimo, B.4
Cloud, G.A.5
Lee, J.Y.6
Alldredge, L.7
Hunter, E.8
Lambert, D.9
Bolognesi, D.10
Matthews, T.11
Johnson, M.R.12
Nowak, M.A.13
Shaw, G.M.14
Saag, M.S.15
-
49
-
-
0028953212
-
The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure
-
C. Wild, T. Greenwell, D. Shugars, L. Rimsky-Clarke, and T. Matthews The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure AIDS Res. Hum. Retroviruses 11 1995 323 325
-
(1995)
AIDS Res. Hum. Retroviruses
, vol.11
, pp. 323-325
-
-
Wild, C.1
Greenwell, T.2
Shugars, D.3
Rimsky-Clarke, L.4
Matthews, T.5
-
50
-
-
34547854349
-
Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus
-
J.J. Dwyer, K.L. Wilson, D.K. Davison, S.A. Freel, J.E. Seedorff, S.A. Wring, N.A. Tvermoes, T.J. Matthews, M.L. Greenberg, and M.K. Delmedico Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus Proc. Natl. Acad. Sci. U. S. A. 104 2007 12772 12777
-
(2007)
Proc. Natl. Acad. Sci. U. S. A.
, vol.104
, pp. 12772-12777
-
-
Dwyer, J.J.1
Wilson, K.L.2
Davison, D.K.3
Freel, S.A.4
Seedorff, J.E.5
Wring, S.A.6
Tvermoes, N.A.7
Matthews, T.J.8
Greenberg, M.L.9
Delmedico, M.K.10
-
51
-
-
79952781156
-
In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor
-
Z. Liu, M. Shan, L. Li, L. Lu, S. Meng, C. Chen, Y. He, S. Jiang, and L. Zhang In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor J. Biol. Chem. 286 2010 3277 3287
-
(2010)
J. Biol. Chem.
, vol.286
, pp. 3277-3287
-
-
Liu, Z.1
Shan, M.2
Li, L.3
Lu, L.4
Meng, S.5
Chen, C.6
He, Y.7
Jiang, S.8
Zhang, L.9
-
52
-
-
80055013474
-
Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function
-
D. Eggink, I. Bontjer, J.P. Langedijk, B. Berkhout, and R.W. Sanders Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function J. Virol. 85 2011 10785 10797
-
(2011)
J. Virol.
, vol.85
, pp. 10785-10797
-
-
Eggink, D.1
Bontjer, I.2
Langedijk, J.P.3
Berkhout, B.4
Sanders, R.W.5
-
54
-
-
0030162962
-
Therapy of HIV infections: Problems and prospects
-
D.D. Ho Therapy of HIV infections: problems and prospects Bull. N. Y. Acad. Med. 73 1996 37 45
-
(1996)
Bull. N. Y. Acad. Med.
, vol.73
, pp. 37-45
-
-
Ho, D.D.1
-
55
-
-
63149114263
-
Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors
-
C. Pan, H. Lu, Z. Qi, and S. Jiang Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors AIDS 23 2009 639 641
-
(2009)
AIDS
, vol.23
, pp. 639-641
-
-
Pan, C.1
Lu, H.2
Qi, Z.3
Jiang, S.4
|